These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16732027)

  • 21. Diabetes costs rise, but so does adherence.
    Manag Care; 2005 Apr; 14(4):54. PubMed ID: 15898213
    [No Abstract]   [Full Text] [Related]  

  • 22. Diabetes drugs in England cost nearly £1bn last year.
    Kmietowicz Z
    BMJ; 2016 Aug; 354():i4324. PubMed ID: 27492677
    [No Abstract]   [Full Text] [Related]  

  • 23. Medication regimen complexity in patients with uncontrolled hypertension and/or diabetes.
    Rettig SM; Wood Y; Hirsch JD
    J Am Pharm Assoc (2003); 2013; 53(4):427-31. PubMed ID: 23892818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus.
    Dore DD; Chaudhry S; Hoffman C; Seeger JD
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):209-13. PubMed ID: 21254293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying factors that affect patients' willingness to pay for inhaled insulin.
    Pinto SL; Holiday-Goodman M; Black CD; Lesch D
    Res Social Adm Pharm; 2009 Sep; 5(3):253-61. PubMed ID: 19733826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy.
    Berger J
    Am J Manag Care; 2007 Apr; 13 Suppl 2():S55-8. PubMed ID: 17417934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care.
    Piette JD; Wagner TH; Potter MB; Schillinger D
    Med Care; 2004 Feb; 42(2):102-9. PubMed ID: 14734946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology and costs of diabetes treated with insulin in France.
    Detournay B; Raccah D; Cadilhac M; Eschwège E
    Diabetes Metab; 2005 Jun; 31(3 Pt 2):3-18. PubMed ID: 16142041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of a value-based insurance design plus health coaching on medication adherence and medical spending.
    Musich S; Wang S; Hawkins K
    Popul Health Manag; 2015 Jun; 18(3):151-8. PubMed ID: 25247449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in antidiabetic medication intensity among Medicare beneficiaries with diabetes mellitus.
    Stuart B; Shaffer TJ; Simoni-Wastila LJ; Zuckerman IH; Quinn CC
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):195-208. PubMed ID: 17996659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery.
    Makary MA; Clark JM; Shore AD; Magnuson TH; Richards T; Bass EB; Dominici F; Weiner JP; Wu AW; Segal JB
    Arch Surg; 2010 Aug; 145(8):726-31. PubMed ID: 20713923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does increased adherence to medications change health care financial burdens for adults with diabetes?
    Miller GE; Sarpong EM; Hill SC
    J Diabetes; 2015 Nov; 7(6):872-80. PubMed ID: 25817601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ready, set, go.
    Kassien L
    Diabetes Forecast; 2014 Jan; 67(1):30-1. PubMed ID: 25868291
    [No Abstract]   [Full Text] [Related]  

  • 34. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study.
    Heinze G; Hronsky M; Reichardt B; Baumgärtel C; Müllner M; Bucsics A; Winkelmayer WC
    Appl Health Econ Health Policy; 2015 Apr; 13(2):193-205. PubMed ID: 25536928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin therapy in NWFP Pakistan.
    Ahmad M
    J Ayub Med Coll Abbottabad; 2001; 13(3):36-7. PubMed ID: 11873397
    [No Abstract]   [Full Text] [Related]  

  • 38. The new economics of diabetes management.
    Manag Care Interface; 2000; Suppl D():1-31. PubMed ID: 11187887
    [No Abstract]   [Full Text] [Related]  

  • 39. Patient adherence to medication requirements for therapy of type 2 diabetes.
    Bailey CJ; Kodack M
    Int J Clin Pract; 2011 Mar; 65(3):314-22. PubMed ID: 21314869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New diabetes insurance laws present challenges for states.
    J Am Diet Assoc; 1998 May; 98(5):514. PubMed ID: 9597020
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.